Olverembatinib approved for commercialization in Macau China
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dyslipidemia is a critical risk factor for cardiovascular diseases
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Subscribe To Our Newsletter & Stay Updated